Abstract
The renin-angiotensin system has been established as an attractive target for pharmacological intervention since the discovery of first angiotensin-converting enzyme inhibitors (ACE-Is). In fact, these drugs are primarily used in the management of cardiovascular system-related diseases and renal insufficiency. Their mechanism of action involves the adjustment of balance between vasoconstrictive, hypertrophic and salt/water-retentive angiotensin II and vasodilatory and natriuretic bradykinin by the inhibition of angiotensin II biosynthesis and bradykinin degradation. Currently there are thirteen family members approved for use in humans. They differ in structure, chemistry and pharmacokinetic and pharmacodynamic properties yet they display a similar pharmacologic and toxicologic profile. All of them are effective in the treatment of hypertension as well as in cardiac insufficiency or diabetic nephropathy. Although they are generally well-tolerated several serious side-effects including life-threatening angioedema, renal failure and persistent dry cough could occur during the administration of ACE-Is, which may require the cessation of therapy. Furthermore, to provide maximum safety and efficiency of ACE-Is-based therapy, the knowledge of the related drug interactions and chronokinetics seems to be an absolute requirement. Here we discuss the above-mentioned issues regarding the pharmaceutical and chemical properties of the commercially- used ACE-Is.
Keywords: Hypertension, pharmacotherapy, interactions, the renin-angiotensin system.
Current Pharmaceutical Design
Title:Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors
Volume: 21 Issue: 13
Author(s): Milosz Regulski, Katarzyna Regulska, Beata J. Stanisz, Marek Murias, Paulina Gieremek, Anna Wzgarda and Bartlomiej Niznik
Affiliation:
Keywords: Hypertension, pharmacotherapy, interactions, the renin-angiotensin system.
Abstract: The renin-angiotensin system has been established as an attractive target for pharmacological intervention since the discovery of first angiotensin-converting enzyme inhibitors (ACE-Is). In fact, these drugs are primarily used in the management of cardiovascular system-related diseases and renal insufficiency. Their mechanism of action involves the adjustment of balance between vasoconstrictive, hypertrophic and salt/water-retentive angiotensin II and vasodilatory and natriuretic bradykinin by the inhibition of angiotensin II biosynthesis and bradykinin degradation. Currently there are thirteen family members approved for use in humans. They differ in structure, chemistry and pharmacokinetic and pharmacodynamic properties yet they display a similar pharmacologic and toxicologic profile. All of them are effective in the treatment of hypertension as well as in cardiac insufficiency or diabetic nephropathy. Although they are generally well-tolerated several serious side-effects including life-threatening angioedema, renal failure and persistent dry cough could occur during the administration of ACE-Is, which may require the cessation of therapy. Furthermore, to provide maximum safety and efficiency of ACE-Is-based therapy, the knowledge of the related drug interactions and chronokinetics seems to be an absolute requirement. Here we discuss the above-mentioned issues regarding the pharmaceutical and chemical properties of the commercially- used ACE-Is.
Export Options
About this article
Cite this article as:
Regulski Milosz, Regulska Katarzyna, Stanisz J. Beata, Murias Marek, Gieremek Paulina, Wzgarda Anna and Niznik Bartlomiej, Chemistry and Pharmacology of Angiotensin-Converting Enzyme Inhibitors, Current Pharmaceutical Design 2015; 21 (13) . https://dx.doi.org/10.2174/1381612820666141112160013
DOI https://dx.doi.org/10.2174/1381612820666141112160013 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
2-Methoxyestradiol as a Potential Cytostatic Drug in Gliomas?
Anti-Cancer Agents in Medicinal Chemistry Immunotherapy in Allergies: An Update
Inflammation & Allergy - Drug Targets (Discontinued) The Structure-property Relationships of Clinically Approved Protease Inhibitors
Current Medicinal Chemistry Factors Associated with Self-Reported Drug Allergies in a Large Chronic Spontaneous Urticaria Cohort
Current Drug Safety Naproxen: An Update on Physicochemical, Analytical and Pharmacological Aspects
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach
Current Medicinal Chemistry Seasonal Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery Ethnicity and Drug Therapy for Hypertension
Current Pharmaceutical Design Complement and Complement Regulatory Proteins as Potential Molecular Targets for Vascular Diseases
Current Pharmaceutical Design Topomer CoMFA and Virtual Screening Studies of Azaindole Class Renin Inhibitors
Combinatorial Chemistry & High Throughput Screening Time-Dependent Effects in Chronic Urticaria: A Time-Series Perspective of Omalizumab Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets Nephroangiosclerosis and Its Pharmacological Approach
Current Vascular Pharmacology A New Binding Site Involving the C-terminal Domain to Design Specific Inhibitors of PepX
Protein & Peptide Letters Structure Function Analysis of Serpin Super-Family: "A Computational Approach"
Protein & Peptide Letters Systematic Review on Infusion Reactions Associated with Chemotherapies and Monoclonal Antibodies for Metastatic Colorectal Cancer
Current Clinical Pharmacology Cardiovascular Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Macrolides Allergy
Current Pharmaceutical Design Meet the Editorial Board Member
Recent Patents on Inflammation & Allergy Drug Discovery Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Sacubitril/Valsartan: A New Dawn has Begun! A Revisited Review
Current Cardiology Reviews